Product data sheet

MedKoo Cat#: 326792 Name: Otamixaban CAS: 193153-04-7 (free base) Chemical Formula: $C_{25}H_{26}N_4O_4$ Exact Mass: 446.1954 Molecular Weight: 446.507	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years.
	In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:
Otamixaban, also known as XRP0673, is an experimental injectable anticoagulant direct factor Xa inhibitor, that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.

2. CoA, QC data, SDS, and handling instruction
SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	50.0	119.98

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.24 mL	11.20 mL	22.40 mL
5 mM	0.45 mL	2.24 mL	4.48 mL
10 mM	0.22 mL	1.12 mL	2.24 mL
50 mM	0.05 mL	0.22 mL	0.45 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator
Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study
In vitro study

Hempel T, Elez K, Krüger N, Raich L, Shrimp JH, Danov O, Jonigk D, Braun A, Shen M, Hall MD, Pöhlmann S, Hoffmann M, Noé F. Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties. Chem Sci. 2021 Aug 26;12(38):12600-12609. doi: 10.1039/d1sc01494c. PMID: 34703545; PMCID: PMC8494051.

In vivo study

TBD

7. Bioactivity
Biological target:

Otamixaban (FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor.

In vitro activity

This study reports that a late-stage drug candidate, otamixaban, inhibits SARS-CoV-2 cell entry. This study shows that otamixaban suppresses TMPRSS2 activity and SARS-CoV-2 infection of a human lung cell line, although with lower potency than camostat or nafamostat. In contrast, otamixaban inhibits SARS-CoV-2 infection of precision cut lung slices with the same potency as camostat.

Product data sheet

Furthermore, this study reports that otamixaban's potency can be significantly enhanced by (sub-) nanomolar nafamostat or camostat supplementation.

Reference: Chem Sci. 2021 Aug 26;12(38):12600-12609. https://pubmed.ncbi.nlm.nih.gov/34703545/

In vivo activity

TBD

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.